Uncategorized
Full-year guidance gets withdrawn as earnings roll in
admin | April 24, 2020
This document is intended for institutional investors and is not subject to all of the independence and disclosure standards applicable to debt research reports prepared for retail investors. This material does not constitute research.
Earnings season is well underway, and more companies are pulling full year guidance given the uncertainty surrounding the pandemic. The lack of visibility is forcing management teams to rethink sales and profit targets that were set pre-COVID-19, and provided investors with a new perspective for assessing relative value. Opportunities among companies that have pulled guidance include Kimberly Clark (KMB), which has benefited greatly from consumers stockpiling paper goods; and Quest Diagnostics (DGX), which just started COVID-19 antibody testing, but has yet to offset the loss of revenues related to routine medical and employment testing.
Kimberly Clark (KMB – A2/A)
KMB witnessed organic sales growth of 11% during the quarter as volumes increased more than 8%. The growth largely came from the Consumer Tissue Segment which saw sales and volume growth of 13% and 14%, respectively, driven by toilet paper stockpiling. Adjusted operating profit was up a strong 24% to $997 milion, reflecting cost savings from restructuring programs coupled with lower pulp input costs. This led to a 250 bp year-over-year expansion of the adjusted operating profit margin (to 19.9%). Additionally, cash from operations was $704 million, up from $317 million in the year ago period.
Even with strong results, KMB continues to prudently manage its balance sheet and further strengthen liquidity. KMB executed two debt deals during the quarter for a total of $1.25 billion, with proceeds being used to pre-fund its August maturities ($500 million) as well as for cash on hand to reduce its commercial paper needs. At quarter end, liquidity was a solid $3.73 billion, as KMB’s two credit facilities totaling $2.75 billion remain untapped and the company had $979 million of cash on hand. KMB also announced that it would temporarily suspend its share repurchase program (effective 4/24/20) to provide additional liquidity, underscoring its commitment to maintain its single-A credit ratings.
Relative Value : While KMB should be considered a core hold during the pandemic, their on the run bonds seem to be somewhat fairly valued for the mid-single A ratings. Spreads look comfortable across the curve, with the most value seen in the KMB 2037 and 2041 bonds. Although these particular bonds are hard to source, they provide an attractive pick in yield whether investors are looking to add or shorten duration.
Exhibit 1: Single-A Consumer Products Curve
Source: Bloomberg TRACE
Concessions Get Squeezed
Quest Diagnostics (Baa2/BBB+/BBB)
DGX got off to a good start in the quarter with management noting that January and February results were consistent with full year guidance. However, they witnessed a material decline in March as volumes dropped over 40% in the last two weeks of the month. That said, revenues were down 3.8% year-over-year, to $1.82 billion, however they still beat consensus estimates of $1.75 billion. Furthermore adjusted EPS of $0.94 beat street estimates of $0.86. Adjusted operating income fell over 21% (to $225 million) with the margin contracting 280 bp (to 12.3%). Management noted that the year-over-year operating margin decline was entirely due to the revenue decline in March. Prior to March, DGX had witnessed a meaningful improvement to the operating margin driven by strong volumes and revenue growth.
Liquidity is good as DGX ended the quarter with $342 million of cash on hand and borrowing capacity under its unsecured revolver and secured receivables facility of $1.3 billion. DGX did note that in April it drew down $100 million on each facility. While the company remains in compliance with covenants under the facilities, including a 3.5x maximum leverage covenant, they are in advanced talks with their lead lender to amend the covenant as they believe it would be breached by the end of 2Q. Management is confident that the covenant will be amended before quarter end. They also noted that their IG ratings help to provide them access to alternate sources of financing should it become necessary. In an effort to shore up liquidity, DGX has suspended its share repurchase program for the rest of the year.
Exhibit 2: BBB Healthcare/CVS/ DGX Curves
Source: Bloomberg TRACE
Relative Value: While the ramp up in antibody testing should help DGX to offset some lost revenues and volume declines, the potential for higher leverage for the remainder of the year is a risk. Additionally the sheer drop in revenues at the end of March is alarming, and spreads could drift wider in here particularly if they come with a deal to further enhance liquidity. While DGX’s spread curve closely matches that of its BBB peers, investors should be more comfortable owning the CVS Health credit (CVS – Baa2/BBB), as CVS has already tapped the market. CVS bonds largely trade though DGX across the curve, but the relationship between the two credits is reversed in the 30-year sector.
This material is intended only for institutional investors and does not carry all of the independence and disclosure standards of retail debt research reports. In the preparation of this material, the author may have consulted or otherwise discussed the matters referenced herein with one or more of SCM’s trading desks, any of which may have accumulated or otherwise taken a position, long or short, in any of the financial instruments discussed in or related to this material. Further, SCM may act as a market maker or principal dealer and may have proprietary interests that differ or conflict with the recipient hereof, in connection with any financial instrument discussed in or related to this material.
This message, including any attachments or links contained herein, is subject to important disclaimers, conditions, and disclosures regarding Electronic Communications, which you can find at https://portfolio-strategy.apsec.com/sancap-disclaimers-and-disclosures.
Important Disclaimers
Copyright © 2024 Santander US Capital Markets LLC and its affiliates (“SCM”). All rights reserved. SCM is a member of FINRA and SIPC. This material is intended for limited distribution to institutions only and is not publicly available. Any unauthorized use or disclosure is prohibited.
In making this material available, SCM (i) is not providing any advice to the recipient, including, without limitation, any advice as to investment, legal, accounting, tax and financial matters, (ii) is not acting as an advisor or fiduciary in respect of the recipient, (iii) is not making any predictions or projections and (iv) intends that any recipient to which SCM has provided this material is an “institutional investor” (as defined under applicable law and regulation, including FINRA Rule 4512 and that this material will not be disseminated, in whole or part, to any third party by the recipient.
The author of this material is an economist, desk strategist or trader. In the preparation of this material, the author may have consulted or otherwise discussed the matters referenced herein with one or more of SCM’s trading desks, any of which may have accumulated or otherwise taken a position, long or short, in any of the financial instruments discussed in or related to this material. Further, SCM or any of its affiliates may act as a market maker or principal dealer and may have proprietary interests that differ or conflict with the recipient hereof, in connection with any financial instrument discussed in or related to this material.
This material (i) has been prepared for information purposes only and does not constitute a solicitation or an offer to buy or sell any securities, related investments or other financial instruments, (ii) is neither research, a “research report” as commonly understood under the securities laws and regulations promulgated thereunder nor the product of a research department, (iii) or parts thereof may have been obtained from various sources, the reliability of which has not been verified and cannot be guaranteed by SCM, (iv) should not be reproduced or disclosed to any other person, without SCM’s prior consent and (v) is not intended for distribution in any jurisdiction in which its distribution would be prohibited.
In connection with this material, SCM (i) makes no representation or warranties as to the appropriateness or reliance for use in any transaction or as to the permissibility or legality of any financial instrument in any jurisdiction, (ii) believes the information in this material to be reliable, has not independently verified such information and makes no representation, express or implied, with regard to the accuracy or completeness of such information, (iii) accepts no responsibility or liability as to any reliance placed, or investment decision made, on the basis of such information by the recipient and (iv) does not undertake, and disclaims any duty to undertake, to update or to revise the information contained in this material.
Unless otherwise stated, the views, opinions, forecasts, valuations, or estimates contained in this material are those solely of the author, as of the date of publication of this material, and are subject to change without notice. The recipient of this material should make an independent evaluation of this information and make such other investigations as the recipient considers necessary (including obtaining independent financial advice), before transacting in any financial market or instrument discussed in or related to this material.
Important disclaimers for clients in the EU and UK
This publication has been prepared by Trading Desk Strategists within the Sales and Trading functions of Santander US Capital Markets LLC (“SanCap”), the US registered broker-dealer of Santander Corporate & Investment Banking. This communication is distributed in the EEA by Banco Santander S.A., a credit institution registered in Spain and authorised and regulated by the Bank of Spain and the CNMV. Any EEA recipient of this communication that would like to affect any transaction in any security or issuer discussed herein should do so with Banco Santander S.A. or any of its affiliates (together “Santander”). This communication has been distributed in the UK by Banco Santander, S.A.’s London branch, authorised by the Bank of Spain and subject to regulatory oversight on certain matters by the Financial Conduct Authority (FCA) and the Prudential Regulation Authority (PRA).
The publication is intended for exclusive use for Professional Clients and Eligible Counterparties as defined by MiFID II and is not intended for use by retail customers or for any persons or entities in any jurisdictions or country where such distribution or use would be contrary to local law or regulation.
This material is not a product of Santander´s Research Team and does not constitute independent investment research. This is a marketing communication and may contain ¨investment recommendations¨ as defined by the Market Abuse Regulation 596/2014 ("MAR"). This publication has not been prepared in accordance with legal requirements designed to promote the independence of research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. The author, date and time of the production of this publication are as indicated herein.
This publication does not constitute investment advice and may not be relied upon to form an investment decision, nor should it be construed as any offer to sell or issue or invitation to purchase, acquire or subscribe for any instruments referred herein. The publication has been prepared in good faith and based on information Santander considers reliable as of the date of publication, but Santander does not guarantee or represent, express or implied, that such information is accurate or complete. All estimates, forecasts and opinions are current as at the date of this publication and are subject to change without notice. Unless otherwise indicated, Santander does not intend to update this publication. The views and commentary in this publication may not be objective or independent of the interests of the Trading and Sales functions of Santander, who may be active participants in the markets, investments or strategies referred to herein and/or may receive compensation from investment banking and non-investment banking services from entities mentioned herein. Santander may trade as principal, make a market or hold positions in instruments (or related derivatives) and/or hold financial interest in entities discussed herein. Santander may provide market commentary or trading strategies to other clients or engage in transactions which may differ from views expressed herein. Santander may have acted upon the contents of this publication prior to you having received it.
This publication is intended for the exclusive use of the recipient and must not be reproduced, redistributed or transmitted, in whole or in part, without Santander’s consent. The recipient agrees to keep confidential at all times information contained herein.
